<DOC>
	<DOCNO>NCT00375973</DOCNO>
	<brief_summary>The purpose study determine safety efficacy duloxetine compare placebo reduce fatigue patient diagnose Chronic Fatigue Syndrome ( CFS ) .</brief_summary>
	<brief_title>Double Blind Trial Duloxetine Chronic Fatigue Syndrome</brief_title>
	<detailed_description>Chronic fatigue syndrome ( CFS ) characterize severe disable fatigue least six month duration fully explain identifiable medical condition . Pain symptom also part diagnostic criterion CFS , include muscle pain , multi-joint pain , headache . The prevalence CFS range 0.007 2.8 % general adult population 0.006 3.0 % primary care practice ( 2 ) . Although receive CFS diagnosis 30-40 year age , Caucasian , female , CFS affect woman men , adult child , racial socioeconomic class . Patients CFS 2-4 time rate depression anxiety compare general population . CFS also commonly comorbid fibromyalgia , disorder characterize chronic widespread pain , tenderness , fatigue , sleep mood disturbance . In sample , 70 % patient fibromyalgia also meet criterion CFS . CFS fibromyalgia characterize great similarity difference may share pathophysiologic feature . Like fibromyalgia , CFS associate chronic pain , sleep mood disturbance . Because fibromyalgia responds treatment antidepressant , particularly dual serotonin norepinephrine reuptake inhibitor , include duloxetine , antidepressant trial CFS clearly need .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>1 . Female male outpatient 1865 year age . 2 . Meet criterion revise Center Disease Control ( CDC ) definition Chronic Fatigue Syndrome ( CFS ) ( least 6 month persistent fatigue substantially reduce person 's level activity ; 4 follow symptom must occur fatigue 6month period : impaired memory concentration , sore throat , tender gland , ache stiff muscle , multijoint pain , new headache , unrefreshing sleep , postexertional fatigue . Medical condition may explain fatigue psychiatric disorder , include eat disorder , psychotic disorder , bipolar disorder , melancholic depression , substance abuse within 2 year onset fatigue , exclude ) . 3 . Provision write informed consent participation trial . 4 . Educational level degree understand patient communicate intelligibly investigator study staff . 5 . Judged reliable agree keep appointment clinic visit , test , procedure require protocol . 1 . Current melancholic major depressive disorder , previous diagnosis psychosis , eat disorder , bipolar disorder . 2 . History substance abuse dependence within past year , exclude nicotine caffeine . 3 . A positive urine drug screen substance abuse ( may retested positive test prescribe medication wash ) . 4 . Women pregnant breast feeding ; woman must test negative pregnancy Visit 1 . 5 . Women childbearing potential use medically accept mean contraceptive engage sexual intercourse . 6 . Patients , opinion investigator , treatmentrefractory whose response likely compromise exist future disability compensation issue . 7 . Serious unstable medical illness , include cardiovascular , hepatic , renal , respiratory , hematologic illness , unstable medical psychiatric condition opinion investigator would compromise participation would likely lead hospitalization duration study . Abnormal thyroid stimulate hormone ( TSH ) concentration ( unless treatment hypothyroidism stable least past 3 month patient clinically euthyroid ) . 8 . Patients uncontrolled narrowangle glaucoma . 9 . Patients acute liver injury ( hepatitis ) severe cirrhosis ( ChildPugh Class C ) . 10 . Patients judge prior randomization suicidal risk clinical investigator . 11 . Treatment antidepressant medication within 14 day prior randomization exception fluoxetine , use within 30 day prior randomization . Potential need use monoamine oxidase inhibitor ( MAOI ) study within 2 week discontinuation study treatment . 12 . Patients previously take duloxetine 13 . Patients take excluded medication discontinue Visit 1 . 14 . Treatment within last 30 day drug receive regulatory approval time study entry . 15 . Known hypersensitivity duloxetine inactive ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Fatigue</keyword>
	<keyword>Fatigue syndrome , chronic</keyword>
	<keyword>Chronic fatigue syndrome</keyword>
	<keyword>CFS</keyword>
	<keyword>Fibromyalgia</keyword>
</DOC>